A study recently published by researchers from the Mount Sinai hospital system in New York shows that the “vast majority” of patients with mild to moderate symptoms of COVID-19 have antibodies for at least three months.
The study, which has not yet been peer-reviewed, based on nearly 20,000 people with the virus.
“… We report that the vast majority of people infected with mild to moderate COVID-19 experience robust IgG antibody responses against the viral peak protein, based on a dataset of 19,860 individuals examined at the Mount Health System Sinai in New York City, “the researchers wrote in the study summary.
CDC’S “BEST ESTIMATE” IS 40 PERCENT COVID-19 INFECTIONS ARE ASYMPTOMATIC
The researchers continued: “We also showed that the titers are stable for at least an approximate three-month period, and that anti-peak binding titers correlate significantly with neutralization of authentic SARS-CoV-2. Our data suggests that more of 90 [percent] of seroconverters produce detectable neutralizing antibody responses and that these titers are stable at least in the short term. “
The study has been published on the medRxiv server.
The researchers looked at the plasma of 121 donors to determine how long the antibodies responded to the peak proteins in SARS-CoV-2. The peak protein in SARS-CoV-2 is what the virus uses to bind to human cells.
The research result found that approximately 50 percent of the sera in the 80 to 160 range neutralized the spike proteins, while 90 percent of those in the 320 range had neutralizing capabilities. All those in the 960-2880 range had neutralizing activity.
The researchers noted that understanding mild cases of COVID-19 is important since mild and asymptomatic patients are widely believed to make up the vast majority of cases.
Last week, the Centers for Disease Control and Prevention updated their “best estimate”, noting that 40 percent of COVID-19 infections are asymptomatic.
GILEAD SAYS THAT TREATMENT WITH CORONAVIRUS REMDESIVIR REDUCES THE RISK OF DEATH IN SERIOUS COVID-19 PATIENTS
Although the study is not yet able to provide “conclusive evidence” that the antibodies protect against reinfection, “the researchers believe that they are very likely to decrease the likelihood of re-infection and to attenuate the disease in the event of an infection. advanced, “Mount said. The Sinai spokesman told Fox News in an email.
A separate study by researchers at St. George’s, University of London, found that the antibodies could remain stable in the blood of an infected person for two months after diagnosis. The study also found that no antibodies were detected in all participants.
CLICK HERE FOR FULL CORONAVIRUS COVERAGE
As of Monday morning, more than 14.5 million cases of coronaviruses have been diagnosed worldwide, of which more than 3.7 million are in the United States, the most affected country on the planet.
GET THE FOX NEWS APP
Fox News’ Kayla Rivas contributed to this article.